- Review
- Open access
- Published:
Practical solutions for hypertensive patients with dyslipidemia
Artery Research volume 18, pages 49–54 (2017)
Abstract
Arterial hypertension and dyslipidemia often coexist and constitute major risk factors of ischemic heart disease. Aggressive treatment of both comorbidities is of paramount importance to decrease global risk. Low adherence is a determinant of poor risk factor control and increases adverse cardiovascular outcomes. Regarding treatment of hypertension, combination therapy is superior in achieving target BP values compared to up-titrating monotherapy and it is recommended in hypertension guidelines. The combined use of drugs in a single pill formulation increases adherence and reduces cardiovascular risk. Our review of the literature indicates that triple therapy with an angiotensin converting enzyme inhibitor, a calcium channel blocker and a statin is associated with a significant reduction in major cardiovascular events. This is attributed to synergy at the vascular, and is translated into efficacy at the clinical level.
References
World Heart Organization. Global atlas on cardiovascular disease prevention and control. WHO Press; 2011.
Chapman RH, Benner JS, Petrilla AA, Tierce JC, Collins SR, Battleman DS, et al. Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 2005; 165(10):1147–52.
Thoenes M, Bramlage P, Zhong S, Shang S, Volpe M, Spirk D. Hypertension control and cardiometabolic risk: a regional perspective. Cardiol Res Pract 2012;2012. 925046.
Jackson R, Lawes CM, Bennett DA, Milne RJ, Rodgers A. Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute cardiovascular risk. Lancet 2005;365(9457):434–41.
Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Böhm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. J Hum Hypertens 2010;24(5):336–44.
Gyberg V, Kotseva K, Dallongeville J, Backer GD, Mellbin L, Rydén L, et al., EUROASPIRE Study Group. Does pharmacologic treatment in patients with established coronary artery disease and diabetes fulfill guideline recommended targets? A report from the EUROASPIRE III cross-sectional study. Eur J Prev Cardiol 2015;22(6):753–61.
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11,000 participants from 42 trials. Am J Med 2009; 122(3):290–300.
van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012;33(16): 2088–97.
Cheng J, Zhang W, Zhang X, Han F, Li X, He X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014;174(5): 773–85.
Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005;46(2):386–92.
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359(23):2417–28.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al., ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489):895–906.
Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011 Feb; 124(2):128–35.
Athyros VG, Mikhailidis DP, Papageorgiou AA, Bouloukos VI, Pehlivanidis AN, Symeonidis AN, et al., GREACE Study Collaborative Group. Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. J Hum Hypertens 2004;18(11):781–8.
Bertrand ME, Ferrari R, Remme WJ, Simoons ML, Deckers JW, Fox KM, EUROPA Investigators. Clinical synergy of perindopril and calcium-channel blocker in the prevention of cardiac events and mortality in patients with coronary artery disease. Post hoc analysis of the EUROPA study. Am Heart J 2010; 159(5):795–802.
Bertrand ME, Vlachopoulos C, Mourad JJ. Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. Am J Cardiovasc Drugs 2016;16(4): 241–53.
Sever P, Dahlo¨f B, Poulter N, Wedel H, Beevers G, Caulfield M, et al., ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian cardiac outcomes trial. Eur Heart J 2006; 27(24):2982–8.
Ferrari R. Optimizing the treatment of hypertension and stable coronary artery disease: clinical evidence for fixed-combination perindopril/amlodipine. Curr Med Res Opin 2008;24(12):3543–57.
Rubba P. Effects of atorvastatin on the different phases of atherogenesis. Drugs 2007;67(Suppl. 1):17–27.
Mason RP. Mechanisms of plaque stabilization for the dihydropyridine calcium channel blocker amlodipine: review of the evidence. Atherosclerosis 2002 Dec;165(2):191–9.
Vlachopoulos C, Aznaouridis K, Dagre A, Vasiliadou C, Masoura C, Stefanadi E, et al. Protective effect of atorvastatin on acute systemic inflammation-induced endothelial dysfunction in hypercholesterolaemic subjects. Eur Heart J 2007;28(17):2102–9.
Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the effect of angiotensin-converting enzyme inhibitors on the rate of endothelial cell apoptosis: in vitro and in vivo studies. Cardiovasc Drugs Ther 2007;21(6): 423–9.
Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J 2010;31(15):1865–71.
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318–27.
Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al., CAFE Investigators, Anglo-Scandinavian Cardiac Outcomes Trial Investigators, CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113(9):1213–25.
Nichols WW, O’Rourke MF, Vlachopoulos C. McDonald’s blood flow in arteries: theoretic, experimental and clinical principles. 6th ed. London, UK: Edward Arnold; 2011.
Vlachopoulos C, Terentes-Printzios D, Tousoulis D. The phar-macodynamics of arterial stiffness. In: Laurent S, Cockcroft J, editors. Central aortic blood pressure. Paris, France: Servier; 2015.
Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis 2012;221:18–33.
Böhm M, Schumacher H, Laufs U, Sleight P, Schmieder R, Unger T, et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013;166(2):306–14.
Vlachopoulos C, Xaplanteris P. What is the role of combination therapy in treating hypertension? Dialogues Cardiovasc Med 2015;20:15–23.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120(8):713–9.
Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, et al. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. BMJ 2014;348:g3318.
Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013; 34(38):2940–8.
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016 Oct 14;37(39):2999–3058 [Epub 2016 Aug 27].
Emberson J, Whincup P, Morris R, Walker M, Ebrahim S. Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease. Eur Heart J 2004;25(6):484–91.
Yusuf S, Lonn E, Pais P, Bosch J, López-Jaramillo P, Zhu J, et al., HOPE3 Investigators. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med 2016;374(21):2032–43.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article was presented as lecture in the symposium on “Protecting arteries against hypertension and dyslipidemia” at the ARTERY 16 Congress in Copenhagen, Denmark (October 13–15, 2016).
Rights and permissions
This is an open access article distributed under the CC BY-NC license. https://doi.org/creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Vlachopoulos, C., Ioakeimidis, N. Practical solutions for hypertensive patients with dyslipidemia. Artery Res 18, 49–54 (2017). https://doi.org/10.1016/j.artres.2017.03.002
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/j.artres.2017.03.002